Education & Training
- 1986-1990 B.A. Chemistry, University of North Carolina at Chapel Hill (with honors and distinction)
- Graduate:1990-1995 Johns Hopkins Medical School M.D. Baltimore, MD
- Graduate: 1993-1998 Johns Hopkins Medical School Ph.D. Immunology Baltimore, MD
- 1995-1996 Department of General Surgery John L. Cameron, MD Johns Hopkins Hospital Surgery Baltimore, MD
- 1996-2000 Residency in Otolaryngology Charles W. Cummings, MD Head and Neck Surgery, Johns Hopkins Hospital
Choby GW, Kim J, Ling DC, Abberbock S, Mandal R, Kim S, Ferris RL, Duvvuri U. Transoral robotic surgery alone for oropharyngeal cancer: quality-of-life outcomes. JAMA Otolaryngol Head Neck Surg. 2015 Jun;141(6):499-504.
Griffith CC, Pai RK, Schneider F, Duvvuri U, Ferris RL, Johnson JT, Seethala RR. Salivary gland tumor fine-needle aspiration cytology: a proposal for a risk stratification classification. Am J Clin Pathol. 2015 Jun;143(6):839-53
Maxwell JH, Thompson LD, Brandwein-Gensler MS, Weiss BG, Canis M, Purgina B, Prabhu AV, Lai C, Shuai Y, Carroll WR, Morlandt A, Duvvuri U, Kim S, Johnson JT, Ferris RL, Seethala R, Chiosea SI. Early Oral Tongue Squamous Cell Carcinoma: Sampling of Margins From Tumor Bed and Worse Local Control. JAMA Otolaryngol Head Neck Surg. 2015 Jul 30:1-8.
Ferris RL, Baloch Z, Bernet V, Chen A, Fahey TJ 3rd, Ganly I, Hodak SP, Kebebew E, Patel KN, Shaha A, Steward DL, Tufano RP, Wiseman SM, Carty SE; American Thyroid Association Surgical Affairs Committee. American Thyroid Association Statement on Surgical Application of Molecular Profiling for Thyroid Nodules: Current Impact on Perioperative Decision Making. Thyroid. 2015 Jul;25(7):760-8.
Holsinger FC, Ferris RL.Transoral Endoscopic Head and Neck Surgery and Its Role within the Multidisciplinary Treatment Paradigm of Oropharynx Cancer: Robotics, Lasers, and Clinical Trials. J Clin Oncol. 2015 Sep 8. pii: JCO.2015.62.3157.
Chapman, BV, Wald Al, Akhtar P, Munko AC, Xu J, Gibson SP, Grandis JR, Ferris RL, Khan SA. MicroRNA-363 targets myosin 1B to reduce cellular migration in head and neck cancer. BMC Cancer 2015 Nov 6;15:861.
Li J, Srivastava RM, Ettyreddy A, Ferris RL. Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients. J Immunother Cancer. 2015 Nov 17;3:54. 2015.
Concha-Benavente, F, Srivastava, RM, Trivedi, S, Y Lei, U Chandran, RR. Seethala5, GJ. Freeman, and RL Ferris. Identification of the cell-intrinsic and extrinsic pathways downstream of EGFR and IFNγ that induce PD-L1 expression in head and neck cancer. Cancer Research,in press
Garcia-Bates Tatiana, Kim Eun, Concha-Benavente, Trivedi Sumita, Mailliard Robbie B, Gambotto Andrea, Ferris RL. Enhanced cytotoxic CD8 T cell priming using DC expressing HPV-16 E6/E7- p16INK4 fusion protein with sequenced anti-PD1. Journal of Immunology, 2016 March 15 196/6/2429 featured by the “In this Issue” section (Top 10% of articles published in the journal)
Lei Y, Kansy B, Li J, Cong L, Liy Y, Trivedi S, Wen H, Timg JPY, Ouyang H, and Ferris RL. EGFR- targeted mAb therapy modulates autophagy in head and neck squamous cell carcinoma through NLRX1-TUFM protein complex. Oncogene, in press
Research Interest Summary
Dr. Ferris is a head and neck surgical oncologist with an NIH R01 funded basic/translational immunology laboratory. He investigates mechanisms of anti-tumor immunity in the microenvironment, as well as immune escape mechanisms developed by tumor cells to evade NK and T cells elimination. Dr. Ferris’s lab also studies immune checkpoint receptors and cellular immune mechanisms of anti-tumor responses and immunotherapy in phase I and phase II clinical trials, as well as correlative studies of immune markers in the serum and tumor microenvironment. Dr. Ferris is the UPCI Associate Director for Translational Research, Co-Leader of the Cancer Immunology Program, and the recently funded Tumor Microenvironment Center. In these capacities, his goals are to facilitate and enhance development of new targets and therapeutic agents through collaborative, trans-disciplinary preclinical research and clinical application. These include immunosuppressive effects which inhibit clinical activity of cetuximab, including suppressive immunologic effects and immune escape mechanisms by tumor cells in cetuximab treated patients. Dr. Ferris is pleased to serve as contact PI of the NCI P50 Head and Neck SPORE, to further facilitate preclinical and clinical investigations, and to stimulate new collaborations. He was elected surgical oncology Co-Chair of the NCI Head and Neck Steering committee, which provides additional opportunities to leverage translational and clinical oncology research. As co-chair of the ECOG H&N committee, Dr. Ferris is leading two prospective randomized trials. ECOG 3311 (accrual 268/515) investigates the potential for surgical deintensification through reduced radiation dose in HPV+ oropharyngeal cancer patients treated with transoral robotic or laser surgery. More recently ECOG-ACRIN 3132 compares adjuvant radiation alone vs. cisplation-radiation in patients with disruptive or nondisruptive p53 alteration, using a molecular biomarker of “high risk” status.
NCI NCTN-Network Lead Academic Site, 03/01/16-02/28/17, Co-investigator PI: Brufsky, NIH U10 CA180844
SPORE in Head & Neck Cancer, project 3, Wild Type p53, 07/01/15 –06/30/20, Ferris (contact)/Grandis, NIH/NCI P50 CA097190-4
Immune Activation by Cetuximab in Head and Neck Cancer Patients, 7/01/10 –06/30/16, PI: Ferris, 1R01 DE019727-05
SPORE - Head & Neck Cancer “Cellular Immunity and Checkpoint”, 07/01/15-06/30/20, Co-Leader, Project 3, NIH/NCI P50 CA097190-11
FSTRF Subaward Contract #PITTDEVRF-00 under, 2/1/14 –12/31/15, PI: Ferris, Frontier Science
Correlative Studies for Phase III trials of anti-PD-1 Nivolumab vs SOC, 12/31/15 –3/30/17, PI: Ferris, Bristol-Myers Squibb
Characterization of Novel Immuno-therapeutic Targets in HNSCC TIL, 12/31/15 –12/30/17, PI: Ferris, AZ/Medimmune
Postdoctoral Research Training in Head and Neck Oncology, 09/01/15-08/31/20, PI: Ferris, NIH/NCI T32 CA060397-20
Cancer Center Support Grant Senior Leadership, Associate Director for Translational Research, 78/01/15 -06/30/20, Co-Investigator PI: Davidson, NIH/NCI P30 CA047904-22
Cancer Center Support Grant Co-Leader – Cancer Immunology Program, 07/01/15-06/30/20, Co-Investigator (PI: Davidson), NIH/NCI P30 CA047904-24
Molecular Imaging of Metastatic Potential in SCCHN by Targeting VLA-4 and CXCR4, 07/01/2013-06/30/2016, Co-Investigator (PI: Anderson), NIH/NCI R21CA180211-02